Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is primarily developing vintafolide, a SMDC that targets the platinum-resistant ovarian cancer, non-small cell lung cancer, triple negative breast cancer, and carboplatin/paclitaxel combination; and etarfolatide, a proprietary companion imaging agent for vintafolide. The company is also developing product candidates for colorectal, prostate, kidney, endometrial, solid tumors, and other cancers, as well as for chronic inflammatory disorders. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.